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Bovine seminal ribonuclease (BS-RNase), a dimeric homologue of RNase A, cleaves both single- and double-stranded RNA and inhibits the growth 
of tumor cells. Its catalytic activity against double-stranded RNA, either homopolymeric (PH]polyA/polyU) or mixed sequence, is enhanced by 
bovine or human recombinant interferon-y (IFN-y). Activation is seen with as little as 4-10 interferon units per assay. Enhancing the degradation 
of double-stranded RNA, an intermediate in the growth cycle of many viruses, could contribute to IFN-y’s ability to control cell growth and induce 
an antiviral state. 
Interferon-y; Interferon-u; Ribonuclease A (RNase A); Bovine seminal ribonuclease; Mechanism of cell growth inhibition by interferons; 
Activation of double-stranded RNA degradation 
1. INTRODUCTION 
Increased synthesis or translation of specific mes- 
senger RNAs in cells treated by interferons (IFN) [l] is 
considered to be the most probable mechanism for the 
induction by interferon of an antiviral state and its in- 
hibition of cell growth. However, recent evidence has 
indicated that interferons may also influence the stabili- 
ty [2,3] and processing [4] of mRNAs. As interferons 
also inhibit angiogenesis in vitro [5] and in vivo [6] and 
as factors capable of inducing angiogenesis include a 
ribonuclease homologue (angiogenin) and, possibly, 
ribonucleoproteins [7], we have undertaken a study of 
the interaction between interferons and ribonucleases. 
2. MATERIALS AND METHODS 
We first found that IFN--y preparations timulate the catalytic ac- 
tivity of the non-digestive RNase from bovine seminal fluid (BS- 
RNase) (but not RNase A or B), when single-stranded RNA is the 
substrate [8]. Bovine seminal ribonuclease has a relatively higher ac- 
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tivity on double-stranded (ds) RNA substrates than RNase A. We 
show here that IFN-7 stimulates even more the activity of BS-RNase, 
but not of RNase A, when the substrate in the nuclease assay is 
homopolymeric @olyA/polyU) or mixed sequence double-stranded 
(ds) RNA. Activation of mixed sequence ds-RNA cleavage is observed 
at concentrations (l-500 IFN units/ml, l-2 nM [9]) that are 
physiologically relevant. 
3. RESULTS AND DISCUSSION 
The catalytic activity of BS-RNase against homopo- 
lymeric ds-RNA [3H]polyA/polyU) is increased by 
human recombinant IFN-7, while the activity of RNase 
A is either unaffected or, at high concentrations, in- 
hibited by IFN-7 (Table I). This inhibition, which is 
also seen at very high concentrations of IFN-7 in the 
assays of single- and double-stranded mixed sequence 
RNA, is probably related to the fact that IFN-y binds 
RNA tightly [8]. (This binding can also be seen in Fig. 2 
when high concentrations (> 200-300 IFU/assay or > 1 
rg/ml of the human IFN) are added.) 
When human IFN-y is preincubated with monoclonal 
or polyclonal antibodies that neutralize its activity in 
antiviral assays and inhibit its binding to cell-surface 
receptors, its ability to activate BS-RNase is lost (Table 
II). Antibodies (such as monoclonal antibody y-127) 
which bind but do not neutralize IFN-y do not lower the 
ability of IFN-y to activate BS-RNase. Monoclonal an- 
tibody y-69, which is about lOO-fold more inhibitory 
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Table I Table II 
Comparison of the effect of recombinant human IFN-7 on the rate of 
hydrolysis of double-stranded RNA catalyzed by RNase A and bovine 
seminal ribonuclease 
Antibodies to human IFN-7 neutralize their activation effect on 
bovine seminal ribonuclease in the percentage RNA solubilized assay 
using double-stranded RNA [‘H]polyA/polyU) 
Addition Percentage Percentage 
ds RNA control 
solubilized activity 
Buffer 
Buffer plus IFN-7, 0.5 mg/ml 
BS-RNase, 0.2 mg/ml 
(1) RNase A, 0.1 mg/ml 
idem + human IFN-7 at: 
5.10-’ mg/ml 
5. lo-’ mg/ml 
5 lo-’ mg/ml 
(2) BS-RNase, 0.02 mg/ml 
idem + human IFN-7 at: 
5.10-l mg/ml 
5.10-* mg/ml 
5. lo-’ mg/ml 
(3) BS-RNase, 0.002 mg/ml 
idem + human IFN-7 at: 
5.10-l mg/ml 
5.10-* mg/ml 
5. lo-’ m&ml 
13 
11 
91 
61 (1W 
31 50 
61 112 
56 89 
22 
51 489 
15 689 
21 100 
17 
20 
43 
16 
(1W 
(1W 
175 
750 
100 
Like interferon isolated from natural sources, the human IFN-y used 
lacks Cys-Tyr-Cys at the N-terminus. IFN-yA Cys (1 ~1 of the in- 
dicated dilution) was combined with 1 ~1 of BS-RNase or RNase A 
(diluted to the indicated concentration in BSA/Tris), 5 ~1 of ‘ds- 
RNase assay mix’ was added, the samples incubated 1 h at 37°C the 
reactions topped with the addition of TCA and carrier RNA and pro- 
tein, and the pellet collected by centrifugation as described [8]. 
[‘H]PolyA/polyU was prepared by combining 50 pl (~40 pmol) 
[3H]polyadenylic acid (n = 50) with 0.8 mg polyuridylic acid (Phar- 
macia) in 200~1 HrO. The sample was heated to 80°C for 15 min and 
then cooled slowly to room temperature. The ‘ds-RNase assay mix’ 
contained 30~1 of the annealed substrate in 500~1 of Tris buffer, pH 
7.9,25 mM, which gave about 1250 cpm per assay (dissolved in Rotis- 
zint 22 (Roth)). Note the buffer control (13% of the total RNA is acid 
soluble due to the inhomogeneity of the substrate) must be 
substracted from all numbers to determine the percentage RNA 
solubilized by the enzyme. ‘pecentage control activity’ is the activity 
of the sample containing IFN-7 relative to that of the nuclease alone 
than y-123 in the antiviral assay, also inhibits the activa- 
tion of BS-RNase more than r-123. Both of the 
neutralizing antibodies bind to human IFN-7 near 
residue 80 (Garotta, G., personal communications). 
Monoclonal antibody y-127 binds to a basic region of 
IFN-7 near the C-terminus. 
Recombinant human IFN-02, human interleukin-2 
and murine IFN-cu have no effect on the activity of BS- 
RNase on either single- or double-stranded RNA 
substrates (data not shown). Nor does lysozyme, 
another positively charged protein, have a marked ef- 
fect. At very high concentrations lysozyme partially in- 
hibits the cleavage of ss-RNA but not the rate of 
cleavage of ds RNA (Table III). Lysozyme, like IFN-7, 
Addition Percentage Percentage 
RNA control 
solubilized 
Buffer control 
BS-RNase plus buffer 
BS-RNase + : 
15 
30, 30 (100) 
no antibody, y diluted in PBS-BSA 
monoclonal 127, 35 pg (non- 
neutralizing) 
monoclonal 123, 31 gg (weakly 
neutralizing) 
monoclonal 69, 40 pg (y-neutralizing) 
affinity-purified polyclonal, 43 pg 
(y-neutralizing) 
42, 44 181 
44, 48 207 
34, 35 133 
29, 28 93 
35, 39 141 
IFN-y (250 ng, diluted with 1 mg/ml macaloid treated (to remove 
ribonucleases [l 1) BSA in PBS) was added to PBWBSA buffer (con- 
trol) or to lO,ul of antibody in PBS (containing the indicated amount 
of protein), the samples were incubated for 5 h at 4°C and centrifuged 
in an Eppendorf centrifuge for 15 min. For the assay, 2~1 of a 5.10-’ 
mg/ml solution of BS-RNase in PBWBSA were combined with 2 pl 
of the preincubated IFN-y containing solution, the ds-RNA nuclease 
assay mix was added (see Table I), the samples were incubated 1 h at 
37”C, and stopped by addition of TCA and carrier protein and RNA. 
None of the antibody solutions alone contained appreciable nuclease 
activity in this assay nor did they activate the nuclease. Antibodies (in 
PBS) were obtained from G. Garotta of Roche Research, Basel; 
neutralization of IFN-7 activity was determined by inhibition of IFN- 
y activity in the antiviral assay (in Zurich) and its binding to cells (in 
Basel). Note the buffer control (15% of the total RNA is acid soluble 
due to the inhomogeneity of the substrate) must be substracted from 
all numbers to determine the percentage RNA solubilized by the en- 
zyme. ‘Percentage control’ is the activity of the sample containing 
IFN-y relative to that of the nuclease alone (based on the average of 
duplicate samples) 
binds RNA tightly at high concentrations (data not 
shown), and we believe this accounts for the RNase in- 
hibition observed. 
IFN-y also activates BS-RNase and inhibits RNase A 
when the substrate in the nuclease reaction is heterose- 
quence double-stranded (ds) RNA. This is presumably 
a biologically more relevant substrate than the homo- 
polymer. Indeed, a nuclease active on double-stranded 
RNA substrates was recently reported to be co-induced 
with IFN-7 [lo]. Both human (Figs. lb and 2b) and 
bovine (Figs.lb and 2c) IFN-7 markedly increase the 
rate of cleavage of ds-RNA by BS-RNase. In contrast, 
both bovine and human IFN-7 inhibit the cleavage of 
ds-RNA by RNase A (Figs. la and 2a), an inhibition 
that correlates well with the binding of the substrate ds- 
RNA by the IFN-y’s (Fig. 2a). 
With either substrate approximately a 3-lo-fold 
molar excess of interferon-y must be added to activate 
BS-RNase. Relatively more BS-RNase must be used to 
degrade the homopolymeric substrate than the mixed 
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Table III 
Comparison of the effect of recombinant human interferon-yA Cys 
with that of another positively charged protein, hen egg lysozyme 
(Sigma), on the activity of bovine seminal ribonuclease against single- 
stranded (ss-RNA) and double-stranded (ds-RNA) RNA 
Addition: 
Buffer 
BS-RNase plus buffer 
Percentage 
ss-RNA 
solubilized 
293 
54, 47 (100) 
Percentage 
ds-RNA 
solubilized 
11 
33, 31 (100) 
BS-RNase + human IFN-* at: 
0.5 mg/ml 
5.10-* mg/ml 
5. 10m3 mg/ml 
5. 10e4 mg/ml 
65 (127) 
67 (131) 
69 (135) 
70 (137) 
54, 75 (255) 
65, 47 (214) 
24, 22 (57) 
not done 
BS-RNase + lysozyme at: 
1 mg/ml 
10-l mg/ml 
lo-* mg/ml 
10m3 mg/ml 
10e4 mg/ml 
10 ( 20) 
41 ( 80) 
68 (133) 
62 (122) 
45 ( 88) 
26 (71) 
43, 34 (131) 
30, 34 (100) 
25, 27 (71) 
not done 
The proteins (1~1 of the indicated dilution in BSA/Tris) were combin- 
ed with 1~1 of a solution of BS-RNase (2. 10e4 mg/ml in BSA/Tris) 
and assayed for ss-RNase activity as described in Fig. 1 or with 1 ~1 
of a lo-’ mg/ml solution of BS-RNase and assayed for activity on 
[“H]polyA/polyU (ds-RNA) as described in Table I. Some samples 
were simultaneously duplicated, as indicated. The numbers in paren- 
theses indicate the percentage RNA solubilized relative to that 
solubilized by the nuclease alone 
sequence ds RNA; consequently, more IFN-7 is needed 
to show activation. Approximately the same activation 
was seen whether the buffer was low salt (Tris, 25 mM, 
used in most experiments) or relatively high salt (PBS, 
Table II). 
These data are interesting for several reasons. First, 
the RNase activation reported here is the first assay for 
the activity of an interferon that does not require mam- 
malian cell culture. As little as 3-4 IFN units can be 
detected if the gel assay of Fig. 2 is used, making it as 
sensitive as the most commonly used antiviral assay. 
While the antiviral assay takes 2-3 days, the RNase 
stimulation assay takes 2-3 h. Of course, the presence 
of nucleases in many biological fluids means that the 
assay is only possible with at least partially purified 
samples of interferon. 
Further, antibodies that block the biological activity 
of IFN-7 in vivo inhibit the ability of IFN-y to activate 
BS-RNase in vitro, and the activity of antibodies that 
block the activation of BS-RNase by IFN-y correlates 
with their ability to neutralize the activity of IFN-7 in 
two different mammalian cell assays. Of course, many 
viruses produce ds-RNA at some point in their growth 
cycle. The ability to bind nucleic acids and to regulate 
the activity of molecules involved in their degradation, 
demonstrated in this study, may be involved in the 
biological function of IFN-y. 
b BS-RNase 
a RNase A 
+ bovine IFN-gamma 
+ human IFN-gamma 
ES-RNase alone. no IFN 
0.01 0.1 1 10 100 1000 10000 0.01 0.1 1 10 100 1000 10000 
IFWassay IFUlasssy 
Fig. 1. Effect of human recombinant IFN-yACys and bovine IFN-7 on the activity of RNase A and bovine seminal RNase (BS-RNase) against 
ds-RNA. Complementary ss-RNA transcripts of a section of the T7 phage genome (ca. 300 bp long, cloned in opposite orientations downstream 
of the promoter for T7 RNA polymerase at the BumHI site of plasmid PET-1 1121) were prepared from EcoRV digests of the purified plasmids 
using T7-RNA polymerase. The ss-RNA was purified by polyacrylamide gel electrophoresis as previously described [8]. To make ds-RNA, equal 
amounts of the labeled ss-RNAs were combined, heated for 5 min to 55”C, and allowed to cool slowly to room temperature. The ds-RNA was 
degraded at least 100 x more slowly by RNase A and had a much slower mobility on polyacrylamide gels than the corresponding ss-RNAs. (a) 
RNase A (0.02 rig/assay,, diluted in 1 mg/ml Macaloid-treated BSA in 25 mM Tris-HCl, pH 7.9, (BSA/Tris)) was combined with dilutions of 
human and bovine IFN-7 in the same buffer. ‘Nuclease assay mix’ (ca. 200000 cpm/ml double-stranded ‘*P-labeled RNA in 25 mM Tris/HCl, 
pH 7.9) was added (final sample volume was 8 cl), samples were incubated 40 min at 37”C, the assay was stopped with cold 10% TCA, and 5 
~1 of a solution of 20 mg/ml of BSA and 40 fig/ml of RNA were added as carriers. Samples were incubated for 30 min on ice, and centrifuged 
10 min at 4°C in an Eppendorf centrifuge. The supernatant and pellet fractions were counted separately, and the data expressed as percent of total 
RNA in the supernatant fraction. (b) Ds-RNA degradation by BS-RNase (0.2 rig/assay)) in the presence of varying concentrations of IFN-7. Assays 
were essentially run as above but incubated 60 min at 37°C before TCA addition. Duplicate samples were averaged. 
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+ ES-RNase (0.2 rig/assay)) ,-,o 
+7 
I 
+ bo IFN-Y +7 ali 
400 0 0.04 0.4 4 40 400 I I 0 400 0 IFWassav 
no +bo +hu 
+ RNase A(0.02 rig/assay)) “o 
=+L”f Y 
+bo IFN +hu IFN add, 
0 400 3000 0 4oT400 300~000 0 0 IFU/assay 
- shifted ds RNA 
uncleaved ds RNA 
ds RNA degradation 
products 
- shifted ds RNA 
- uncleawl ds RNA 
ds RNA degradation 
products 
c 
+SS-RNase (0.2 rig/assay)) 
+Y I I + hu IFN-Y I I +Y g 
IFUlassay 
- shifted ds RNA 
- uncleaved ds RNA 
Fig. 2. Autoradiographs of gel assays demonstrating the effect of 
human and bovine recombinant IFN-y on the degradation of ds-RNA 
by RNase A (a) and BS-RNase (b,c). The ds-RNA nuclease assay mix 
(see Fig. 1) was added to buffer (‘no add.‘), to nuclease + / - IFN-y 
(the same dilutions as in Fig. l), or to IFN-7 dilutions without 
nuclease (‘ + IFN-7’). Assays were stopped after incubation for 60 
min at 37°C by adding 4~l/sample of 80% buffered formamide and 
cooling in an ice-salt bath. The mixtures were then applied to a non- 
denaturing 5% polyacrylamide minigel (Hoefer system) in 50 mM 
Tris-borate buffer plus 1 mM EDTA, and electrophoresed at 200 V 
with cooling. Gels were soaked for 30 min in cold 10% TCA, vacuum 
L ds RNA degradation dried onto a nitrocellulose filter (Sartorius, 0.2pm) at 6O”C, covered products with tape, and autoradiographed with or without intensifying screens at -70°C. 
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